Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

170 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Neoadjuvant chemotherapy and radiotherapy for locally advanced breast cancer: Safety and efficacy of reverse sequence compared to standard technique?
Maire M, Debled M, Petit A, Fournier M, Macgrogan G, Quenel-Thueux N, Charitansky H, Mathoulin-Pelissier S, Bonnefoi H, Tunon de Lara C. Maire M, et al. Among authors: bonnefoi h. Eur J Surg Oncol. 2022 Aug;48(8):1699-1705. doi: 10.1016/j.ejso.2022.04.022. Epub 2022 Apr 29. Eur J Surg Oncol. 2022. PMID: 35523623
Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome?
Bonnefoi H, Diebold-Berger S, Therasse P, Hamilton A, van de Vijver M, MacGrogan G, Shepherd L, Amaral N, Duval C, Drijkoningen R, Larsimont D, Piccart M. Bonnefoi H, et al. Ann Oncol. 2003 Mar;14(3):406-13. doi: 10.1093/annonc/mdg108. Ann Oncol. 2003. PMID: 12598346 Free article. Clinical Trial.
Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial.
Bonnefoi H, Potti A, Delorenzi M, Mauriac L, Campone M, Tubiana-Hulin M, Petit T, Rouanet P, Jassem J, Blot E, Becette V, Farmer P, André S, Acharya CR, Mukherjee S, Cameron D, Bergh J, Nevins JR, Iggo RD. Bonnefoi H, et al. Lancet Oncol. 2007 Dec;8(12):1071-1078. doi: 10.1016/S1470-2045(07)70345-5. Epub 2007 Nov 19. Lancet Oncol. 2007. PMID: 18024211 Retracted. Clinical Trial.
Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.
BIG 1-98 Collaborative Group; Mouridsen H, Giobbie-Hurder A, Goldhirsch A, Thürlimann B, Paridaens R, Smith I, Mauriac L, Forbes J, Price KN, Regan MM, Gelber RD, Coates AS. BIG 1-98 Collaborative Group, et al. N Engl J Med. 2009 Aug 20;361(8):766-76. doi: 10.1056/NEJMoa0810818. N Engl J Med. 2009. PMID: 19692688 Free PMC article. Clinical Trial.
[Biomarkers of endocrine therapy-resistance in breast cancers].
de Cremoux P, Debled M, Bonnefoi H, Cottu P. de Cremoux P, et al. Among authors: bonnefoi h. Bull Cancer. 2010 Aug;97(8):951-63. doi: 10.1684/bdc.2010.1137. Bull Cancer. 2010. PMID: 20605764 Free article. Review. French.
TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.
Bonnefoi H, Piccart M, Bogaerts J, Mauriac L, Fumoleau P, Brain E, Petit T, Rouanet P, Jassem J, Blot E, Zaman K, Cufer T, Lortholary A, Lidbrink E, André S, Litière S, Lago LD, Becette V, Cameron DA, Bergh J, Iggo R; EORTC 10994/BIG 1-00 Study Investigators. Bonnefoi H, et al. Lancet Oncol. 2011 Jun;12(6):527-39. doi: 10.1016/S1470-2045(11)70094-8. Epub 2011 May 11. Lancet Oncol. 2011. PMID: 21570352 Free PMC article. Clinical Trial.
170 results